Bioinvent: Partner agreements the key to unlocking the case
Research Update
2019-09-20
07:30
The Bioinvent stock has underperformed the broader market during 2019 (-35%), mainly due to the rights issue earlier this year. We believe much negative already is priced in the share, and see a risk/reward skewed towards the upside.
KP
Klas Palin
Disclosures and disclaimers